

10-2202

1645\$

AMENDMENT TRANSMITTAL LETTER (Large Entity)

Applicant(s): Thomas EMRICH, et al.

Docket No.

BMID9913US

Serial No.
09/284,787Filing Date
April 20, 1999Examiner
Robert ZemanGroup Art Unit
1645Invention: MONOCLONAL ANTIBODIES AGAINST THE EPITOPE YPYDVPDYA, A PROCESS FOR THEIR
PRODUCTION AND THEIR USE

OCT 21 2002

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

RECEIVED
OCT 25 2002
TECH CENTER 1600/2900

CLAIMS AS AMENDED

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	8 -	20 =	0	x \$18.00	\$0.00
INDEP. CLAIMS	3 -	3 =	0	x \$84.00	\$0.00
Multiple Dependent Claims (check if applicable)		<input type="checkbox"/>			\$0.00
					TOTAL ADDITIONAL FEE FOR THIS AMENDMENT
					\$0.00

- No additional fee is required for amendment.
- Please charge Deposit Account No. _____ in the amount of _____
A duplicate copy of this sheet is enclosed.
- A check in the amount of _____ to cover the filing fee is enclosed.
- The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-0877
A duplicate copy of this sheet is enclosed.
- Any additional filing fees required under 37 C.F.R. 1.16.
- Any patent application processing fees under 37 CFR 1.17.


Signature

Dated: October 21, 2002

Kenneth J. Waite, Reg. No. 45,189
 Roche Diagnostics Corporation
 9115 Hague Road, Bldg D
 P.O. B x 50457
 Indianapolis, IN 46250-0457
 Telephone: (317) 521-3104
 Facsimile: (317) 521-2883

I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence

cc:

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)

Applicant(s): Thomas EMRICH et al.

Docket No.

BMID9913US

Serial No.
09/284,787Filing Date
August 16, 1999Examiner
Robert ZemanGroup Art Unit
1645**Invention: MONOCLONAL ANTIBODIES AGAINST THE EPITOPE YPYDVPDYA, A PROCESS FOR THEIR PRODUCTION AND THEIR USE****RECEIVED**
OCT 25 2002
TECH CENTER 1600/2900I hereby certify that this Amendment and Response, Extension and Sequence Listing
*(Identify type of correspondence)*is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under
37 CFR 1.10 in an envelope addressed to: The Commissioner of Patents and Trademarks, Washington, D.C.20231-0001 on October 21, 2002
*(Date)*Michele Wilson*(Typed or Printed Name of Person Mailing Correspondence)*
*(Signature of Person Mailing Correspondence)*EL841986284US*("Express Mail" Mailing Label Number)*

Note: Each paper must have its own certificate of mailing.



RECEIVED

OCT 25 2002

TECH CENTER 1600/2900

Attorney Docket No. BMID 9913US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Thomas EMRICH, *et al.*

Application No.: 09/284,787 Group No.: 1645

Filed: August 16, 1999 Examiner: Robert Zeman

For: Monoclonal Antibodies Against The Epitope YPYDVPDYA, A Process For Their Production And Their Use

Assistant Commissioner for Patents
Washington, D.C. 20231

STATEMENT BY ATTORNEY OF RECORD REGARDING BIOLOGICAL DEPOSIT

I, Kenneth J. Waite, Attorney of Record in the above-captioned matter, hereby state to the best of my knowledge and belief, the following:

1. On October 8, 1996, the hybridoma cell line designated as R3A12 was deposited under the terms of the Budapest Treaty at the Deutsche Sammlung für Mikroorganismen und Zellkulturen ("DSMZ") under the Accession number DSM AC2286

2. This deposit is demonstrated by the attached documents, pages 18 and 20 from the originally filed PCT application pertaining to the above-captioned matter.

3. All restrictions imposed by depositor on the availability to the public of the deposited material will be removed upon the granting of a patent requiring the use of this material.

Respectfully submitted,



Date: Monday, Oct 21, 2002

Kenneth J. Waite, Reg. NO. 45,189
Roche Diagnostics Corporation
9115 Hague Road, Bldg. D
Indianapolis, IN 46250-0457
Telephone: (317) 521-3104
Fax: (317) 521-2883